Northwest Biotherapeutics

Northwest Biotherapeutics Overview

Founded 1996
Status Public
Employees 17
Stock Symbol NWBO
Stock Symbol
Investments 1
Share Price $0.34 (As of Wednesday Closing)

Northwest Biotherapeutics General Information


Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Contact Information

Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Primary Industry
Drug Discovery
Other Industries
Stock Exchange
Primary Office
  • 4800 Montgomery Lane
  • Suite 800
  • Bethesda, MD 20814
  • United States
+1 (240) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Northwest Biotherapeutics Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.34 $0.32 $0.14 - $0.42 $213M 660M 2.22M -$0.05

Northwest Biotherapeutics Financials Summary

In Thousands,
TTM 30-Sep-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017 FY 2016 31-Dec-2016
EV 156,185 137,122 100,252 73,141
Revenue 0 0 0 0
EBITDA (28,024) (24,632) (67,159) (76,207)
Net Income (32,619) (35,794) (73,143) (80,214)
Total Assets 10,145 24,667 48,907 52,906
Total Debt 18,551 16,797 31,429 31,711
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Northwest Biotherapeutics Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Northwest Biotherapeutics‘s full profile, request access.

Request a free trial

Northwest Biotherapeutics Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Advanced Proteome Therapeutics Corporate Backed or Acquired Boston, MA 0 00.000 000000000 00.000
000 000000000000 Formerly VC-backed Epalinges, Switzerland 000 00000 00000000 00000
000000000 Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000000 000.00
0000000 Formerly PE-Backed Beijing, China 0000 00.000 000000000 00.000
0000000 00000000 Formerly VC-backed Bothell, WA 0000 00000 000000 - 000 00000

Northwest Biotherapeutics Executive Team (7)

Name Title Board Seat Contact Info
Marnix Bosch Ph.D Chief Technology Officer, Technology
Alton Boynton Ph.D Chief Scientific Officer & Founder
Linda Powers JD Chief Executive Officer & Chief Financial Officer, Finance

4 Former Executives

Northwest Biotherapeutics Board Members (5)

To view Northwest Biotherapeutics‘s full board member team, request access »
Name Representing Role Since
00000 0000000000 Northwest Biotherapeutics Board Member 000 0000
0000000 000000000 Self Director 000 0000

3 Former Board Members

Northwest Biotherapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Northwest Biotherapeutics‘s full profile, request access.

Request a free trial

Northwest Biotherapeutics Acquisitions (1)

To view Northwest Biotherapeutics‘s complete investment and acquisition history, request access »
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 01-Jan-2008 000000000000000000 Biotechnology

Ready to get started?

Request a free trial